Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples
  2. Madan, Taruna; Biswas, Barnali; Varghese, Praveen M.; Subedi, Rambhadur; Pandit,Hrishikesh; Idicula-Thomas, Susan; Kundu, Indra; Rooge, Sheetalnath; Agarwal, Reshu; Tripathi, Dinesh M.; Kaur, Savneet; Gupta, Ekta; Gupta, Sanjeev K.; Kishore, Uday
  3. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. 2021, Jul; 65(1): 41-53.
  1. 2.   Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site
  2. Alexandre, K. B.; Gray, E. S.; Pantophlet, R.; Moore, P. L.; McMahon, J. B.; Chakauya, E.; O'Keefe, B. R.; Chikwamba, R.; Morris, L.
  3. Journal of Virology. 2011, Sep; 85(17): 9039-9050.
  1. 3.   Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate
  2. Kouokam, J. C.; Huskens, D.; Schols, D.; Johannemann, A.; Riedell, S. K.; Walter, W.; Walker, J. M.; Matoba, N.; O'Keefe, B. R.; Palmer, K. E.
  3. Plos One. 2011, Aug; 6(8):
  1. 4.   Anti-HIV microbicide development: targeting the virus is the key
  2. O'Keefe, B. R.
  3. Future Virology. 2011, May; 6(5): 553-556.
  1. 5.   Conformational and Structural Features of HIV-1 gp120 Underlying the Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18
  2. Gift, S. K.; Zentner, I. J.; Schon, A.; McFadden, K.; Umashankara, M.; Rajagopal, S.; Contarino, M.; Duffy, C.; Courter, J. R.; Zhang, M. Y.; Gershoni, J. M.; Cocklin, S.; Dimitrov, D. S.; Smith, A. B.; Freire, E.; Chaiken, I. M.
  3. Biochemistry. 2011, Apr; 50(14): 2756-2768.
  1. 6.   Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain
  2. Wexler-Cohen, Y.; Ashkenazi, A.; Viard, M.; Blumenthal, R.; Shai, Y.
  3. Faseb Journal. 2010, Nov; 24(11): 4196-4202.
  1. 7.   Recent progress in antiretrovirals - lessons from resistance
  2. Adamson, C. S.; Freed, E. O.
  3. Drug Discovery Today. 2008 13(9-10): 424-432.
  1. 8.   Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency
  2. Zhang, M. Y.; Dimitrov, D. S.
  3. Current Pharmaceutical Design. 2007 13(2): 203-212.
  1. 9.   Antibody-based inhibitors of HIV infection
  2. Choudhry, V.; Zhang, M. Y.; Dimitrova, D.; Prabakaran, P.; Dimitrov, A. S.; Fouts, T. R.; Dimitrov, D. S.
  3. Expert Opinion on Biological Therapy. 2006, MAY; 6(5): 523-531.
  1. 10.   Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A
  2. Witvrouw, M.; Fikkert, V.; Hantson, A.; Pannecouque, C.; O'Keefe, B. R.; McMahon, J.; Stamatatos, L.; De Clercq, E.; Bolmstedt, A.
  3. Journal of Virology. 2005, JUN; 79(12): 7777-7784.
  1. 11.   Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4
  2. Yang, Q. E.; Stephen, A. G.; Adelsberger, J. W.; Roberts, P. E.; Zhu, W. M.; Currens, M. J.; Feng, Y. X.; Crise, B. J.; Gorelick, R. J.; Rein, A. R.; Fisher, R. J.; Shoemaker, R. H.; Sei, S.
  3. Journal of Virology. 2005, MAY; 79(10): 6122-6133.
  1. 12.   TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells
  2. Herbeuval, J. P.; Boasso, A.; Grivel, J. C.; Hardy, A. W.; Anderson, S. A.; Dolan, M. J.; Chougnet, C.; Lifson, J. D.; Shearer, G. M.
  3. Blood. 2005 105(6): 2458-2464.
  1. 13.   Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide - Possible recognition of the fusion complex
  2. Gerber, D.; Pritsker, M.; Gunther-Ausborn, S.; Johnson, B.; Blumenthal, R.; Shai, Y.
  3. Journal of Biological Chemistry. 2004, NOV 12; 279(46): 48224-48230.
  1. 14.   The SARS-CoV S glycoprotein
  2. Xiao, X.; Dimitrov, D. S.
  3. Cellular and Molecular Life Sciences. 2004, OCT; 61(19-20): 2428-2430.
  1. 15.   Discovery of a novel class of small-molecule HIV entry inhibitors that target the gp120-binding domain of CD4
  2. Yang, Q.; Roberts, P.; Zhu, W.; Stephen, A.; Adelsberger, J.; Currens, M.; Feng, Y.; Fisher, R.; Rein, A.; Shoemaker, R.; Sei, S.
  3. Antiviral Research. 2004 62(2): A28-A28.
  1. 16.   Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)
  2. Polianova, M. T.; Ruscetti, F. W.; Pert, C. B.; Tractenberg, R. E.; Leoung, G.; Strang, S.; Ruff, M. R.
  3. Peptides. 2003 24(7): 1093-1098.
  1. 17.   Update on D-Ala-Peptide T-Amide (DAPTA): A viral entry inhibitor that blocks CCR5 chemokine receptors
  2. Ruff, M. R.; Polianova, M.; Yang, Q. E.; Leoung, G. S.; Ruscetti, F. W.; Pert, C. B.
  3. Current HIV Research. 2003 1(1): 51-67.
  1. 18.   Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)
  2. Ruff, M. R.; Melendez-Guerrero, L. M.; Yang, Q. E.; Ho, W. Z.; Mikovits, J. W.; Pert, C. B.; Ruscetti, F. A.
  3. Antiviral Research. 2001 52(1): 63-75.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel